Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M158Revenue $M0.3Net Margin (%)-16,084.0Z-Score-0.2
Enterprise Value $M55.9EPS $-1.4Operating Margin %-13,215.7F-Score3
P/E(ttm))0Cash Flow Per Share $-0.9Pre-tax Margin (%)-16,083.7Higher ROA y-yN
Price/Book1.910-y EBITDA Growth Rate %-12.9Quick Ratio4.7Cash flow > EarningsY
Price/Sales05-y EBITDA Growth Rate %9.4Current Ratio4.7Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-76.4Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-107.9Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M55.8ROI % (ttm)-43.5Gross Margin Increase y-yN

Gurus Latest Trades with CYTR

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
CYTRGeorge Soros 2014-06-30 Sold Out $2.92 - $5.31
($3.79)
$ 2.84-25%Sold Out0
CYTRGeorge Soros 2014-03-31 Buy $3.18 - $8.08
($5.96)
$ 2.84-52%New holding, 81800 sh.81,800
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

CYTR is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
CYTR George Soros 2014-06-30000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


CYTR: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Patterson Scott Bradford10% Owner 2013-12-03Buy284,979$2.4416.39view
Patterson Scott Bradford10% Owner 2013-11-07Buy50,000$2.0637.86view
Patterson Scott Bradford10% Owner 2013-04-01Buy4,083$2.75.19view
Patterson Scott Bradford10% Owner 2013-03-20Buy3,980$2.618.81view
Patterson Scott Bradford10% Owner 2013-03-20Buy35,520$2.5810.08view
Patterson Scott Bradford10% Owner 2013-03-13Buy55,360$2.676.37view
Patterson Scott Bradford10% Owner 2012-10-22Buy180,000$2.5113.15view
Patterson Scott Bradford10% Owner 2012-10-18Buy1,200,000$2.513.6view
Patterson Scott Bradford10% Owner 2012-06-28Buy44,824$5.14-44.75view
Patterson Scott Bradford10% Owner 2012-06-25Buy27,462$5-43.2view

Press Releases about CYTR :

    Quarterly/Annual Reports about CYTR:

    News about CYTR:

    Articles On GuruFocus.com
    Weekly CFO Buys Highlight: CYTR, API, CLGX, PLBC, ARTC Mar 05 2012 
    Weekly CEO Buys Highlight: ULBI, BDE, ALNY, CTTR, GFN Feb 27 2012 
    Weekly CFO Buys Highlight: CYTR, PZZI, AGYS, PLBC Feb 27 2012 
    CytRx Corp. Reports Operating Results (10-K) Mar 11 2011 
    CytRx Corp. Reports Operating Results (10-Q) Nov 08 2010 
    CytRx Corp. Reports Operating Results (10-Q) Aug 09 2010 
    CytRx Corp. Reports Operating Results (10-Q) May 06 2010 
    CytRx Corp. Reports Operating Results (10-Q) Nov 09 2009 
    CytRx Reports 2009 Second Quarter Financial Results Aug 10 2009 
    CytRx Corp. Reports Operating Results (10-Q) Aug 07 2009 

    More From Other Websites
    CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium Oct 30 2014
    CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium Oct 30 2014
    CytRx Announces Publication of Preclinical Glioblastoma Data in Neoplasia Oct 29 2014
    Big Board Biotech Stocks in Play This Week Oct 28 2014
    CytRx Announces Publication of Phase 1b/2 Aldoxorubicin Clinical Data in Soft Tissue Sarcoma in... Oct 20 2014
    CytRx Announces Publication of Phase 1b/2 Aldoxorubicin Clinical Data in Soft Tissue Sarcoma in... Oct 20 2014
    CytRx to Present Data from Global Phase 2b Clinical Trial of Aldoxorubicin in First-Line Soft Tissue... Oct 17 2014
    CytRx to Present Data from Global Phase 2b Clinical Trial of Aldoxorubicin in First-Line Soft Tissue... Oct 17 2014
    CytRx Appoints Steven A. Kriegsman as Chairman of the Board Oct 16 2014
    CytRx Appoints Steven A. Kriegsman as Chairman of the Board Oct 16 2014
    CytRx Launches Discovery Laboratory to Develop Albumin-Binding Anti-Cancer Drug Platform Oct 13 2014
    CytRx Initiates Phase 1b Clinical Trial with Combination of Aldoxorubicin and Gemcitabine in... Oct 09 2014
    CytRx Announces Unexpected Passing of Chairman Max Link, PhD Oct 07 2014
    CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of... Sep 30 2014
    CytRx Receives Multiple FDA Orphan Drug Designations for Aldoxorubicin for the Treatment of... Sep 29 2014
    CytRx Updates Presentation Time at BioCentury's 2014 NewsMakers in the Biotech Industry Conference Sep 26 2014
    CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase... Sep 22 2014
    CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference Sep 19 2014
    Federman & Sherwood Investigates CytRx Corporation for Possible Violations of Federal Securities... Sep 16 2014
    Former Louisiana Attorney General and KSF Announce Appointment as Lead Counsel in CytRx Securities... Sep 15 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK